Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 356

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

Open access
Lin, Jessica J., Cardarella, Stephanie, Lydon, Christine A., Dahlberg, Suzanne E., Jackman, David M., Jänne, Pasi A., Johnson, Bruce E.·2016·Journal of Thoracic Oncology

Abstract

Introduction: Activating mutations in the epidermal growth factor receptor gene (EGFR) predict for prolonged progression‐free survival in patients with advanced non–small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (EGFR‐TKIs) versus chemotherapy. Long‐term survival outcomes, however, remain undefined. The objective of this study was to determine the 5‐year survival in these patients and identify clinical factors associated with overall survival (OS). Methods: Patients with EGFR‐mutant metastatic lung adenocarcinoma who had been treated with erlotinib or gefitinib at Dana‐Farber Cancer Institute between 2002 and 2009 were included. OS was analyzed. Results: Among 137 patients, median progression‐free survival and OS were 12.1 months (95% CI: 10.2–13.5) and 30.9 months (95% CI: 28.2–35.7), respectively. Twenty patients (14.6%) were 5‐year survivors. In multivariate analysis, exon 19 deletions (hazard ratio [HR] = 0.63, 95% CI: 0.44–0.91, p = 0.01), absence of extrathoracic (HR = 0.62, 95% CI: 0.41–0.93, p = 0.02) or brain metastasis (HR = 0.48, 95% CI: 0.30–0.77, p = 0.002), and not a current smoker (HR = 0.23, 95% CI: 0.09–0.59, p = 0.002) were associated with prolonged OS. Age; sex; stage at diagnosis; liver, bone, or adrenal metastasis; specific TKI; and line of TKI therapy were not associated with OS. Conclusions: Our data suggest that the rate of 5‐year survival among patients with EGFR‐mutant metastatic lung adenocarcinoma treated with erlotinib or gefitinib is 14.6%. Exon 19 deletions and absence of extrathoracic or brain metastasis are associated with prolonged survival. On the basis of our findings, clinicians can gain an enhanced estimation of long‐term outcomes in this population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2015.12.103

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 356

Metadata

Authors
Lin, J. J., Cardarella, S., Lydon, C. A., Dahlberg, S. E., Jackman, D. M., Jänne, P. A., & Johnson, B. E.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2016-04
Volume
11
Issue
4
Pages
556-565
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2206185841
Cited by
356
References
48
FWCI
13.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. https://app.cochat.ai/papers/10.1016/j.jtho.2015.12.103
The paper
Lin, J. J., Cardarella, S., Lydon, C. A., Dahlberg, S. E., Jackman, D. M., Jänne, P. A., & Johnson, B. E. (2016). Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2015.12.103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.